Table 1.
Relative Costs of Common Therapies Used for Transplant Recipients
| Indication | Therapy | Treatment Cost (AWP*) |
|---|---|---|
| HCV infection | Glecaprevir/pibrentasvir (Mavyret) | $47,520/12 weeks |
| Elbasvir/grazoprevir (Zepatier) | $65,520/12 weeks | |
| Sofosbuvir/velpatasvir (Epclusa) | $89,712/12 weeks | |
| Ledipasvir/sofosbuvir (Harvoni) | $113,400/12 weeks | |
| Daclatasvir (Daklinza) + sofosbuvir (Sovaldi) | $176,400/12 weeks | |
| Hepatitis B virus infection | Entecavir (Baraclude) | $15,996.60/12 months |
| Lamivudine (Epivir) | $5,799.96/12 months | |
| Cytomegalovirus infection | Valganciclovir (Valcyte) | $47,684.52/6 months |
| End organ support | Hemodialysis (Maintenance) | $250,000/12 months |
| Left ventricular assist device (Placement) | $732,000/once | |
| Left ventricular assist device (Maintenance) | $30,000‐$580,000/12 months |
Estimates based on Lexicomp drug data (https://online.lexi.com) and UnitedHealth Group Analysis (2009‐2015).
(US $).